

ALX ONCOLOGY HOLDINGS INC.

RESEARCH AND DEVELOPMENT COMMITTEE CHARTER

Adopted and approved as of January 16, 2025

The Research and Development Committee (the “**Committee**”) of the Board of Directors (the “**Board**”) of ALX Oncology Holdings Inc. (together with its subsidiaries, as applicable, the “**Company**”) has been appointed by the Board to perform the duties and responsibilities set forth in this charter with respect to the Company.

Purpose

The purpose of the Committee will be to support, assist and advise the Board in its general duties of oversight of the Company’s research and development efforts, including as it relates to the research and development strategy, product pipeline and manufacturing thereof, and other clinical, scientific and research and development matters. The Committee will also provide advice on the scientific, technical, medical, or clinical implications of potential business development opportunities.

Composition

1. Membership. The Committee will consist of one or more members of the Board. The members of the Committee will be appointed annually by the Board upon the recommendation of the Corporate Governance and Nominating Committee and will serve until their successors are duly appointed by the Board or until their earlier resignation or removal. The chair of the Committee (the “**Chair**”) will be appointed by the Board. The Board may at any time and in its discretion remove any member of the Committee and may fill any vacancy in the Committee.
2. Qualifications. The Committee shall be comprised of members determined by the Board to have appropriate scientific, medical, or other relevant expertise.
3. Chair. The Chair of the Committee (or in the Chair’s absence, a member designated by the Chair or the Committee) will preside at each meeting of the Committee, set the agendas for the Committee meetings and report regularly to the Board regarding the Committee’s activities.

Responsibilities

The following are the principal recurring responsibilities of the Committee. The Committee may have other duties as are consistent with its function and applicable law, rules and regulations and as the Board and Committee deem appropriate.

1. Research and Development. The Committee will review and advise on the Company’s research and development strategy, plans, pipeline, and other clinical, scientific and research and development matters, including:

- a. Reviewing the Company's research and development strategy as well as the long-term strategic goals and objectives, and monitoring the Company's progress in achieving such goals and objectives;
 - b. Advising the Board on scientific, technological, and research and development matters, and on strategic issues associated with the Company's product pipeline and technology;
 - c. Monitor and assess emerging technologies, scientific advancements, and competitive landscape within the biopharmaceutical industry;
 - d. Evaluating the progress and performance of ongoing research and development projects, clinical trials, and preclinical studies;
 - e. Reviewing the organization, resources and capabilities of the Company's research, analytical, and clinical departments;
 - f. Review and evaluate potential collaborations, partnerships, licensing agreements, and acquisitions as such opportunities relate to research and development;
 - g. Assisting the Company in reviewing, as requested, the capabilities of the Company's current and prospective key scientific, clinical, medical, or technical personnel and engagement with key opinion leaders, and the depth and breadth of the Company's scientific resources;
 - h. Providing oversight and guidance on the allocation of resources for research and development activities, including budgetary considerations;
 - i. Providing oversight with applicable regulatory requirements, ethical standards, and industry best practices in research and development activities;
 - j. Assessing and mitigating risks associated with research and development initiatives, including intellectual property protection, regulatory compliance, and scientific uncertainties; and
 - k. Advising the Board with regard to performance and succession planning of the Company's officers and other leadership of the research and development, manufacturing, medical, and other technical or scientific functions within the Company.
2. Committee Evaluation. The Committee will conduct and present to the Board a periodic self-performance evaluation of the Committee.
 3. Charter. The Committee periodically will review the adequacy of this charter and recommend any proposed changes to the Board for approval.

General

1. The Committee will meet at such times as the Committee will determine. The Committee may meet in person or by telephone or virtually.
2. A majority of the total number of Committee members will constitute a quorum of the Committee.
3. If a quorum is present, a majority of the members of the Committee present will be empowered to act on behalf of the Committee.
4. Minutes are kept of each meeting of the Committee, and the Committee must regularly provide reports of its actions to the Board.
5. The Committee may delegate its authority to subcommittees or the Chair of the Committee when it deems it appropriate and in the best interests of the Company and when such delegation would not violate applicable law, regulation or Nasdaq or SEC requirements.
6. The Committee has the authority to establish its own rules and procedures for notice and conduct of its meetings so long as they are not inconsistent with any provisions of the Company's bylaws that are applicable to the Committee. The Committee may establish its own meeting schedules, which it will provide to the Board.
7. The Committee may invite to its meetings other Board members, Company management and such other persons as the Committee deems appropriate in order to carry out its responsibilities.
8. Members of the Committee can receive such fees, if any, for their service as Committee members as may be determined by the Board in its sole discretion. Members of the Committee may not receive any compensation from the Company except the fees that they receive for service as a member of the Board or any committee thereof.
9. The Committee is authorized to engage independent scientific, medical, technical, and other advisers as it determines necessary to carry out its duties. The Company will provide appropriate funding, as determined by the Committee, for the payment of compensation to any advisers engaged by the Committee pursuant to this subsection.
10. In addition to the powers and responsibilities expressly delegated to the Committee in this charter, the Committee may exercise any other powers and carry out any other responsibilities delegated to it by the Board from time to time consistent with the Company's bylaws and applicable law. The powers and responsibilities delegated by the Board to the Committee in this charter or otherwise shall be exercised and carried out by the Committee as it deems appropriate without requirement of Board approval. While acting within the scope of the powers and responsibilities delegated to it, the Committee shall have and may exercise all the powers and authority of the Board.